FDA critical of stem-cell firm

| | July 3, 2012
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

The Sugar Land company involved in Gov. Rick Perry‘s unlicensed adult stem-cell procedure is rife with basic manufacturing problems, according to the U.S. Food and Drug Administration.

View the original article here: FDA critical of stem-cell firm – MySanAntonio

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend